37.6K
Downloads
51
Episodes
AllergyTalk is a round-up of the latest in the field of allergy and immunology by the American College of Allergy, Asthma and Immunology. In each bi-monthly episode, hosts Gerald Lee, MD, and Merin Kalangara, MD, invite a guest to discuss key articles reviewed in the current issue of AllergyWatch.
Episodes
Saturday Mar 02, 2024
Omalizumab for Food Allergy Part 2: Implementation Into Practice
Saturday Mar 02, 2024
Saturday Mar 02, 2024
Welcome to a special 2 part episode of Allergytalk!
On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In second part of a 2 part series, we will discuss important considerations in implementing omalizumab for food allergy in your practice.
Speakers:
Dr. Sharon Chinthrajah, MD, an associate professor at Stanford University and the Director of the Sean N Parker Center for Allergy and Asthma Research. She is a co-chair of the OUtMATCH study.
Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study.
Important Links:
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312382
Updated FDA label for omalizumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose.
Dr. Chinthrajah has consulted for Genentech and Novartis.
Dr. Vickery has consulted for Genentech and Novartis
Saturday Mar 02, 2024
Omalizumab for Food Allergy Part 1 : Reviewing the Evidence
Saturday Mar 02, 2024
Saturday Mar 02, 2024
Welcome to a special 2 part episode of Allergytalk! On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In first part of a 2 part series, we will review the evidence behind the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH) study that led to this FDA indication. In Part II, we will discuss important considerations in implementing omalizumab for food allergy in your practice.
Speakers:
Dr. Robert Wood, MD, the Julie and Neil Reinhard Professor of Pediatric Allergy and Immunology and Division Director at Johns Hopkins University School of Medicine and Primary Investigator of the OUtMATCH study.
Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study.
Important Links:
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, YovetichN, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312382
Updated FDA label for omalizumab:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose.
Dr. Wood has consulted for Genentech.
Dr. Vickery has consulted for Genentech and Novartis
Thursday Dec 21, 2023
Thursday Dec 21, 2023
For this episode we will be reviewing three articles from the Nov-Dec 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
Tezepelumab Reduces Exacerbations – Even at Lower Eosinophil Counts
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
Predicting Response to Aspirin Therapy in NSAID-ERD
Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.
Can Technology Aid in Asthma Therapy Adherence?
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Thursday Dec 21, 2023
Episode 28: Is IBS a Type of Food Allergy? Nov/Dec 2021
Thursday Dec 21, 2023
Thursday Dec 21, 2023
For this episode we will be reviewing three articles from the Nov-Dec 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Metabolic Changes During Anaphylaxis Vary by Triggers and Severity
Is IBS Caused by Local Food Allergy in the Intestine?
Local immune response to food antigens drives meal-induced abdominal pain.
Biologics: To Stop or Not to Stop, That Is the Question
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Thursday Dec 21, 2023
Episode 26: Do Airborne Peanuts Cause Allergic Reactions? July/Aug 2021
Thursday Dec 21, 2023
Thursday Dec 21, 2023
For today’s episode we will be reviewing articles from the July-Aug 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
When an asthma patient doesn’t respond to biologic, what should we do?
Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy.
Can we reduce lung function loss in asthma?
Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations.
Airborne peanut doesn’t cause clinical significant reactions
Peanuts in the air - clinical and experimental studies.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, Alladapt, Novartis
Thursday Dec 21, 2023
Episode 25: Is Cefazolin Safe in Penicillin Allergic Patients? May/June 2021
Thursday Dec 21, 2023
Thursday Dec 21, 2023
For today’s episode we will be reviewing articles from the May-June 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
AZT Improves Outcomes and Lowers Costs in Uncontrolled Asthma
The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma.
Cefazolin Should Be Used in Most Penicillin Allergic Patients
Assessment of the Frequency of Dual Allergy to Penicillins and Cefazolin: A Systematic Review and Meta-analysis.
Consider IV Fluids Early if Anaphylaxis Doesn’t Respond to Epinephrine
Cardiovascular changes during peanut-induced allergic reactions in human subjects.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Wednesday Dec 20, 2023
AllergyTalk Episode 32: How Does the Atopic March Differ in Black and White Children?
Wednesday Dec 20, 2023
Wednesday Dec 20, 2023
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we are again joined by Dr. Vivian Hernandez-Trujillo from Nicklaus Children’s Hospital and will be reviewing the July-Aug 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose
Dr. Hernandez-Trujillo:
Speaker Takeda, CSL
Advisory boards Takeda, Regeneron, Sanofi
Consultant Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Wednesday Dec 20, 2023
Wednesday Dec 20, 2023
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we are again joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose
Dr. Montanaro has done research with AstraZeneca, Regeneron, Theravance, and Teva
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst, Novartis
Wednesday Dec 20, 2023
AllergyTalk S2E1: Is COVID Vaccine Skin Testing Useful?
Wednesday Dec 20, 2023
Wednesday Dec 20, 2023
Welcome to Season Two of Allergytalk! Starting with this episode, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we are joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis.
First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Thursday May 11, 2023
Severe Pediatric Asthma Miniseries - Episode 3
Thursday May 11, 2023
Thursday May 11, 2023
Episode 3: Severe pediatric asthma-beyond standard therapy, the role of current and future therapies including biologics
Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.
Learning Objectives:
- Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population
- Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population
- Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma
References:
- Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).
- Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021.
- Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14.
- Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)